Literature DB >> 21960908

Current and future therapy for primary sclerosing cholangitis.

Flavia Mendes1.   

Abstract

Entities:  

Year:  2008        PMID： 21960908      PMCID： PMC3093728     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN： 1554-7914


× No keyword cloud information.
  6 in total

Review 1.  Primary sclerosing cholangitis.

Authors:  Flavia D Mendes; Keith D Lindor
Journal:  Clin Liver Dis       Date:  2004-02       Impact factor: 6.126

2.  Elevated serum IgG4 concentration in patients with primary sclerosing cholangitis.

Authors:  Flavia D Mendes; Roberta Jorgensen; Jill Keach; Jerry A Katzmann; Thomas Smyrk; Jessica Donlinger; Suresh Chari; Keith D Lindor
Journal:  Am J Gastroenterol       Date:  2006-07-27       Impact factor: 10.864

3.  Abnormal hepatic biochemistries in patients with inflammatory bowel disease.

Authors:  Flavia D Mendes; Cynthia Levy; Felicity B Enders; Edward V Loftus; Paul Angulo; Keith D Lindor
Journal:  Am J Gastroenterol       Date:  2006-11-13       Impact factor: 10.864

Review 4.  High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis.

Authors:  Timothy Smith; Alex S Befeler
Journal:  Curr Gastroenterol Rep       Date:  2007-03

5.  The impact of ursodeoxycholic acid on cancer, dysplasia and mortality in ulcerative colitis patients with primary sclerosing cholangitis.

Authors:  J M Wolf; L A Rybicki; B A Lashner
Journal:  Aliment Pharmacol Ther       Date:  2005-11-01       Impact factor: 8.171

6.  Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community.

Authors:  Kiran Bambha; W Ray Kim; Jayant Talwalkar; Heidi Torgerson; Joanne T Benson; Terry M Therneau; Edward V Loftus; Barbara P Yawn; E Rolland Dickson; L Joseph Melton
Journal:  Gastroenterology       Date:  2003-11       Impact factor: 22.682
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.